Special Serologic Reagents and Methods

Special methods answer a defined laboratory question by changing the reagent, red cells, or antibody mixture. Interpretation depends on what the method detects, which reactivity it removes, which antigens it alters, and which control confirms that the procedure worked.

Antihuman globulin reagents

Antihuman globulin (AHG) binds the human IgG and complement fragments named on the reagent label. The direct antiglobulin test (DAT) detects coating acquired by red cells in the circulation. The indirect antiglobulin test (IAT) produces sensitization during incubation in the laboratory, then detects the bound globulin after the applicable washing or separation step.^1,2

AHG products may use polyclonal, monoclonal, or blended antibodies. This design changes epitope coverage and product performance, so the label and instructions for use govern reagent selection. An anti-C3d reagent has no anti-C4 activity unless the product separately states that coverage. Hemolysis evidence, transfusion and pregnancy history, drug exposure, and the reaction pattern give a reactive DAT or IAT its clinical meaning.^1,2

Tube-test controls and failure points

In a conventional tube IAT, incubation permits antibody uptake, saline washes remove unbound protein, AHG is added promptly, and calibrated centrifugation produces the endpoint. A negative result is valid only when the procedure’s IgG-sensitized control cells agglutinate after their addition. Complement-detecting methods also use appropriate complement-sensitized controls at the frequency specified by the procedure. Failure of a required control requires the test to be repeated. Each product supplies its own cell concentration, serum or plasma volume, incubation, wash, centrifugation, reading, and daily quality control requirements.^2,3

For example, the cited Alba Bioscience tube anti-IgG reagent uses 2 drops of serum or plasma with 1 drop of a 2% to 4% red-cell suspension, incubates at 37 ± 1 °C for 30 to 60 minutes, washes 3 to 4 times, and then centrifuges the AHG test at 900 to 1000 × g for approximately 10 seconds. These values belong to that product and illustrate why a local procedure must reproduce its own reagent instructions.³

The Blood Group Immunology page explains IgG sensitization, enhancement media, reaction phases, and complement. The pretransfusion testing process places these methods within antibody investigation and unit selection.

Enzymes, enhancement media, and lectins

Proteolytic enzymes such as ficin and papain alter red-cell membrane proteins and can strengthen, weaken, or remove antigen expression. Compare an enzyme-treated panel with untreated cells from the same investigation. A reaction that disappears suggests an antibody directed against an enzyme-sensitive antigen. A stronger reaction can reveal an enzyme-enhanced specificity. The untreated panel remains the source for excluding antibodies whose antigens the enzyme weakens or destroys.^1,4

Enzyme effects vary with the reagent and procedure. An enzyme panel is a supplemental method with its own controls. Albumin, low-ionic-strength solution (LISS), and polyethylene glycol (PEG) change the sensitization environment without enzymatically altering antigen expression. Their use follows the validated antibody-detection system.^1,4

Lectins bind selected carbohydrate structures. Dolichos biflorus anti-A₁ and Ulex europaeus anti-H support ABO subgroup investigations under their reagent instructions. Their patterns are interpreted with forward and reverse grouping, reaction strength, and the patient’s history.¹

Adsorption and elution

Adsorption removes selected antibody from serum or plasma by binding it to cells or another antigen-bearing material. The adsorbed specimen is then tested for reactivity that had been hidden by the removed antibody.

Rabbit erythrocyte stroma can adsorb selected cold autoantibodies. It can also bind anti-B and anti-P1. Do not use RESt-treated serum for reverse grouping or crossmatching. Repeated adsorption can dilute a weak alloantibody, so the final interpretation records the adsorption performed and the remaining exclusions. The warm AIHA testing pathway explains when autoantibody removal enters a patient investigation.^1,5

Elution releases antibody from coated red cells. The recovered fluid is the eluate. Method selection depends on the suspected specificity, available cell volume, required antibody recovery, and whether the cells must remain suitable for further testing.^1,4

Organic-solvent elution methods are now uncommon because they lyse the red cells, expose staff to hazardous chemicals, and offer no routine advantage over safer validated methods.¹

Wash the sensitized cells until the final wash supernatant is nonreactive, then perform the elution. Test that last wash in parallel with the eluate. A reactive last wash shows that residual free antibody has entered the study and invalidates the eluate interpretation.⁴

For a validated ABO HDFN elution, test the eluate with A₁, B, and O cells and include the last-wash control. The O cell helps identify broad or unrelated reactivity. The HDFN laboratory pathway explains neonatal interpretation, including the limited role of routine elution.

Antibody titration

Titration estimates relative antibody concentration through twofold serial dilutions. The reported titer is the reciprocal of the highest dilution that meets the laboratory’s defined reaction endpoint. An optional score assigns values to every reaction grade and adds them across the dilution series, which can reveal a change spread across several tubes or wells.^1,4

Serial comparison requires the same validated method, endpoint, reagent-cell phenotype, cell source, and test conditions. Test the stored baseline specimen beside the current specimen when possible. Prepare dilutions in the direction specified by the procedure and use calibrated pipettes to limit carryover and volume error. Report the method with the result. Tube, column, and solid-phase titers can produce different numeric endpoints.⁴

Endpoint example. A specimen reacts at 1:2, 1:4, 1:8, and 1:16 and reaches the laboratory’s endpoint at 1:16. The reported titer is 16. A later result of 64 is two doubling dilutions higher, a fourfold change. Its significance follows the laboratory’s validated criterion and the clinical testing pathway.

One commonly used score assigns 12 to 4+, 10 to 3+, 8 to 2+, and 5 to 1+. Within that scoring system, a change greater than 10 is commonly treated as significant. The procedure must name the adopted score and its validated cutoff. Passive versus immune anti-D interpretation requires Rh immune globulin history, timing, the reaction pattern, and the trend. The HDFN titer section connects the laboratory result with fetal-risk assessment.¹

Mixed red-cell populations and molecular testing

Recent transfusion can place donor and patient red cells in the same specimen. Serologic antigen typing then reflects both populations. Reference laboratories may enrich a patient-cell fraction, but each method has limits on how completely it separates the populations.

Test a nonseparated specimen in parallel when the procedure requires a mixed-field control. Record the separation method and its residual donor-cell risk with the phenotype.

Blood-group genotyping uses DNA from nucleated cells or another validated specimen to predict an antigen profile. Targeted PCR with sequence-specific primers, probe hybridization, arrays, and DNA sequencing can identify defined alleles or nucleotide changes. Genotyping is useful after recent transfusion, when cells are strongly DAT-positive, or when typing reagents are limited. It also supports extended donor typing and rare-donor searches.^6,7

Genotyping predicts antigen expression; serology demonstrates the antigen expressed on the tested cells. Assay panels cover defined alleles and variants. A result can remain uncertain when a variant falls outside that coverage, when a variant changes expression in an unexpected way, or when hematopoietic transplantation and chimerism make the specimen source unrepresentative of the patient’s inherited genotype. Use current ISBT allele terminology and report the method’s coverage and limitations.^6,7,8

Maternal cell-free DNA can predict selected fetal red-cell antigens under an assay-specific gestational-age and population claim. The HDFN module explains the clinical decision that follows.

Donor nucleic acid testing

Donor nucleic acid testing (NAT) detects pathogen DNA or RNA before serologic markers become detectable. Licensed assays use platform-specific PCR or transcription-mediated amplification (TMA). FDA-authorized products define the specimen, analytes, pool size, controls, and intended use. Current examples include multiplex HIV-1/HIV-2, HCV, and HBV assays and separate WNV assays. Window-period estimates depend on the assay, pooling, specimen, infection stage, and study design, so the current product and FDA testing policy govern interpretation.⁹

Neutralization and thiol reagents

Neutralization uses soluble antigen to bind one antibody in a serum or plasma mixture. Divide the specimen into a neutralized aliquot and a dilution-control aliquot. The control receives an equal volume of saline or the control material named by the procedure. Loss of reactivity only in the neutralized aliquot supports inhibition of the targeted antibody. Remaining reactivity is still investigated for clinically significant alloantibodies.^1,4

High-titer, low-avidity (HTLA) describes a serologic pattern of weak, broad AHG reactivity against high-prevalence antigens. Classical examples include antibodies in the Chido/Rodgers, Knops, and JMH systems. These antibodies usually have little effect on red-cell survival, yet their broad pattern can hide a clinically significant alloantibody. Neutralization, selected enzyme effects, thiol treatment, rare cells, and reference-laboratory testing help define the interference.¹

Dithiothreitol (DTT) and 2-mercaptoethanol reduce disulfide bonds and can disperse IgM pentamers in a treated serum aliquot. Compare treated and untreated aliquots under one validated method when the laboratory question is whether IgM or IgG accounts for reactivity. Concentration, exposure, temperature, and controls determine the result.

DTT treatment of reagent red cells answers a different question. It removes anti-CD38 therapeutic interference by destroying CD38 on the cells, and it also destroys Kell and weakens or destroys other DTT-sensitive antigens. AABB’s updated 2026 guidance recommends K-negative units after DTT-based testing unless the patient is known to be K positive. Antibodies to k, Yt^a, Dombrock, and other DTT-sensitive antigens can escape detection. Baseline or current genotyping, the antibody history, DTT-treated controls, and the approved unit-selection process help account for this residual risk.¹⁰

Column and solid-phase endpoints

Tube, column-agglutination, and solid-phase methods create different visible endpoints. The reagent card, plate, instrument, and instructions for use define the analyte, controls, cell concentration, incubation, centrifugation, wash sequence, and grading rules.^11,12

Column agglutination

In a column card, centrifugation moves unagglutinated cells through the porous matrix to a pellet at the bottom. Agglutinates remain near the top or disperse through the column according to their size. A mixed-field result contains an agglutinated population in the column and an unagglutinated pellet at the bottom. Reaction grades and matrix composition are product-specific.¹²

Read the card within the product’s stated interval. Fibrin, particulates, rouleaux, incorrect cell concentration, drying, and improper centrifugation can create anomalous patterns. Patient transfusion and transplantation history helps determine whether a mixed-field reaction represents two real cell populations. Correlate the pattern with card quality and specimen findings. Column methods incorporate separation within the matrix and use their own positive and negative quality controls.¹²

Solid phase

Solid-phase formats bind red-cell membrane, antigen, antibody, or Protein A to a microplate well. In one FDA-authorized Protein A format, patient serum or plasma and reagent red cells incubate in the coated well. Washing removes unbound protein, anti-IgG links sensitized cells, and centrifugation produces a smooth cell layer for a positive reaction. Unsensitized cells form a compact central button. Other systems use red-cell membrane-coated wells and indicator cells, so the endpoint and controls follow that specific assay.¹¹

Individual solid-phase systems carry defined indications for antibody screening, identification, crossmatch, DAT, or antigen typing. The product label defines the analyte. Platelet and HLA enzyme-linked or multiplex assays use related surface-bound principles with their own antigen panels and signal systems. Interpret the assay through its named analyte, controls, and intended use.

Chloroquine and EGA treatment

An IgG-positive DAT can interfere with antigen typing that uses an IAT phase. Chloroquine diphosphate and EDTA-glycine-acid (EGA) are partial-elution treatments that can remove cell-bound IgG while retaining cells for selected antigen studies. Their antigen effects differ.^1,4

Confirm IgG removal with monospecific anti-IgG after chloroquine treatment because complement can remain and react with polyspecific AHG. Test a known antigen-positive cell through the same treatment when the method requires it. Exposure time, temperature, reagent concentration, and overtreatment limits belong in the procedure. A recent transfusion still makes the remaining cell population unreliable for assigning the patient’s inherited phenotype, even after coating antibody has been removed. Genotyping or reference-laboratory testing resolves that separate problem.^1,5

References

1. Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026.
2. Diagast. Anti-Human Globulin Anti-IgG, Anti-C3d, and Anti-IgG,-C3d Instructions for Use. US Food and Drug Administration. Accessed August 29, 2026.
3. Alba Bioscience Limited. Anti-Human Globulin Anti-IgG Instructions for Use. US Food and Drug Administration. Accessed August 29, 2026.
4. Raman L, Armstrong B, Smart E. Principles of laboratory techniques. ISBT Sci Ser. 2020;15(suppl 1):81-111. doi:10.1111/voxs.12591.
5. Johnson ST, Puca KE. Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies. Hematology Am Soc Hematol Educ Program. 2022;2022(1):96-104. doi:10.1182/hematology.2022000406.
6. Association for the Advancement of Blood & Biotherapies. Standards for Molecular Testing for Red Cell, Platelet, and Neutrophil Antigens. 7th ed. AABB; 2024. Effective January 1, 2025.
7. US Food and Drug Administration. Establishment of Reference Panels for Blood Group Genotyping Tests. Accessed August 29, 2026.
8. International Society of Blood Transfusion. ISBT Blood Group Database. August 2026 release. Accessed August 29, 2026.
9. US Food and Drug Administration. Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays. Accessed August 29, 2026.
10. Association for the Advancement of Blood & Biotherapies. Association Bulletin #16-02: Mitigating the Anti-CD38 Interference With Serologic Testing. Revised March 2026.
11. Bio-Rad Medical Diagnostics GmbH. Solidscreen II Microplate for Solid Phase Antiglobulin Tests With TANGO Instruments Instructions for Use. US Food and Drug Administration. Accessed August 29, 2026.
12. Diagnostic Grifols, SA. DG Gel 8 Cards Instructions for Use. US Food and Drug Administration. Accessed August 29, 2026.